Biomarkers predicting CAR T-cell (CAR T) therapy outcomes in myeloma remain to be established. In this prespecified analysis of the KarMMa trial, Paiva et al. show that persistent measurable residual disease (MRD) around the time of peak expansion correlates with primary resistance to idecabtagene vicleucel. Associations of outcomes with M-protein and circulating plasma cells over the 1-year course were distinct from their profiles following traditional myeloma treatments, highlighting the unique biological mechanism of CAR T therapy. The findings offer one of the first clinical guides to using biomarkers for tailoring salvage therapy following CAR T in myeloma.

See article, p. 365.

The hallmarks of cancer include deregulated cellular metabolism and epigenetic reprogramming. In this work, Toyoda et al. show that a viral oncogene encoded in human T-cell leukemia virus type 1 (HTLV-1), HTLV-1 bZIP factor (HBZ), upregulates TAp73 by its two molecular forms, HBZ RNA and HBZ protein, via...

You do not currently have access to this content.